多中心分析:经颈动脉血运重建与颈动脉内膜剥脱术的比较
本研究回顾性比较了四家机构2013至2017年接受TCAR(经颈动脉血运重建)或CEA(颈动脉内膜剥脱术)的患者,经倾向性匹配后显示两组30天和1年卒中、死亡及复合终点相似,但TCAR组颅神经损伤率更低。
要点
- TCAR与CEA在30天和1年卒中/死亡风险上无显著差异。
- TCAR组颅神经损伤发生率显著低于CEA组(0.3% vs 3.8%)。
- 研究为回顾性设计,需进一步前瞻性比较验证。
核心结论
- TCAR患者即使合并高危合并症,其结局与CEA患者总体相似且颅神经损伤更少。
研究设计与样本
- 回顾性多中心研究,纳入2013至2017年四家机构连续接受TCAR(n=292)或CEA(n=371)的患者,共663例,经1:1倾向性匹配比较。
主要发现
- 匹配前TCAR组糖尿病、高脂血症、冠心病和肾功能不全比例更高。
- 30天卒中/死亡/心肌梗死复合终点2.1% vs 1.7%(P=NS)。
关键数值与推荐
- 匹配样本中症状性患者比例TCAR组36.3%,CEA组35.3%。
临床怎么用
- 对于合并高危因素(如糖尿病、冠心病、肾功能不全)的颈动脉狭窄患者,TCAR可作为CEA的替代选择,尤其关注降低颅神经损伤风险。
局限性
- 回顾性设计,非随机对照,存在选择偏倚。
- 样本来自四家机构,结果外推需谨慎。
- TCAR组患者部分来自前瞻性试验或上市后器械,存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transcarotid artery revascularization (TCAR) is a novel approach to carotid intervention that uses a direct carotid cut-down approach coupled with cerebral blood flow reversal to minimize embolic potential. The initial positive data with TCAR indicates that it may be an attractive alternative to trans-femoral carotid artery stenting and possibly carotid endarterectomy (CEA) for high-risk patients. The purpose of this study was to present 30-day and 1-year outcomes after treatment by TCAR and to compare these outcomes against a matched control group undergoing CEA at the same institutions. METHODS: A retrospective review of all patients who underwent TCAR at four institutions between 2013 and 2017 was performed to evaluate the use of the ENROUTE Transcarotid Neuroprotection System (Silk Road Medical, Inc, Sunnyvale, Calif). TCAR patients had high-risk factors and were either enrolled in prospective trials or treated with a commercially available TCAR device after US Food and Drug Administration approval. Contemporaneous patients undergoing CEA at each institution were also reviewed. Patients were propensity matched in a 1:1 (CEA:TCAR) fashion with respect to preoperative comorbidities. Data were analyzed using statistical models with a P value of less than .05 considered significant. Individual and composite stroke, myocardial infarction, and death at 30 days and 1 year postoperatively were assessed. RESULTS: Consecutive patients undergoing TCAR or CEA were identified (n = 663) and compared. Patients undergoing the TCAR procedure (n = 292) had higher rates of diabetes (P = .01), hyperlipidemia (P = .02), coronary artery disease (P < .01), and renal insufficiency (P < .01) compared with unmatched CEA patients (n = 371). Stroke rates were similar at 30 days (1.0% TCAR vs 1.1% CEA) and 1 year (2.8% TCAR vs 3.0% CEA) in the unmatched groups. After propensity matching by baseline characteristics including gender, age, symptom status (36.3%, 35.3%) and diabetes, 292 TCAR patients were compared with 292 CEA patients. TCAR patients were more likely to be treated preoperative and postoperatively with clopidogrel (preoperatively, 82.2% vs 39.4% [P < .01]; postoperatively, 98.3% vs 36.0% [P < .01]) and statins (preoperatively, 88.0% vs 75.0% [P < .01]; postoperatively, 97.8% vs 78.8% [P < .01]). Stroke (1.0% TCAR vs 0.3% CEA; P = .62) and death (0.3% TCAR vs 0.7% CEA; P = NS) rates were similar at 30 days and comparable at 1 year (stroke, 2.8% vs 2.2% [P = .79]; death 1.8% vs 4.5% [P = .09]). The composite end point of stroke/death/myocardial infarction at 1 month postoperatively was 2.1% vs 1.7% (P = NS). TCAR was associated with a decreased rate of cranial nerve injury (0.3% vs 3.8%; P = .01). CONCLUSIONS: These early data suggest that patients undergoing TCAR, even those with high-risk comorbidities, achieve broadly similar outcomes compared with patients undergoing CEA while mitigating cranial nerve injury. Further comparative studies are warranted.
引用
- Kashyap VS, King AH, Foteh MI, et al. A multi-institutional analysis of transcarotid artery revascularization compared to carotid endarterectomy. J Vasc Surg. 2019. PMID: 30622007. doi:10.1016/j.jvs.2018.09.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。